CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is scheduled to be releasing its earnings data on Monday, August 14th.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Monday, May 15th. The biotechnology company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. On average, analysts expect CASI Pharmaceuticals to post $-0.13 EPS for the current fiscal year and $-0.19 EPS for the next fiscal year.

Shares of CASI Pharmaceuticals, Inc. (NASDAQ CASI) opened at 0.972 on Monday. The firm’s market capitalization is $58.51 million. The stock has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.19. CASI Pharmaceuticals, Inc. has a 52 week low of $0.91 and a 52 week high of $1.76.

Several equities analysts recently issued reports on the stock. Maxim Group reiterated a “buy” rating and set a $4.00 price target on shares of CASI Pharmaceuticals in a research report on Monday, April 17th. ValuEngine upgraded shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th.

TRADEMARK VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/07/casi-pharmaceuticals-inc-casi-scheduled-to-post-earnings-on-monday.html.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.